PRODUCTS
Tongxinluo Capsules
Shensong Yangxin Capsules
Qili Qiangxin Capsule
Lianhua Qingwen Capsules

  • Drug Name: Shensong Yangxin Capsules
  • Approval No.: GYZZ Z20103032
  • Strength: 0.4g/capsule
  • Administration and Dosage: For oral administration, 2-4 capsules once, 3 times daily.
  • Shelf-life: 36 months
  • Ingredients: Ginseng Radix et Rhizoma, Ophiopogonis Radix, Comi Fructus, Salviae miltiorrhizae Radix et Rhizoma, Ziziphi Spinosae Semen (Stir-baked), Taxilli Herba, Paeoniae Radix Rubra, Eupolyphaga seu Steleophaga, Nardostachyos Radix et Rhizoma, Coptidis Rhizoma, Schisandrae Sphenantherae Fructus, Os Draconis.
  • Functions and Indications: Replenish qi and tonify yin, activate blood and free the collateral vessels, nourish the heart to tranquilize. Indicated for ventricular premature beat (VPB) belonging to meridian obstruction syndrome with deficiency of both qi and yin, with the symptoms of palpitation, shortness of breath and hypodynamia, aggravated after moving, oppressed feelings in the precordial region, insomnia and dream disturbed sleep, night sweating, fatigue and lassitude.

The treatment of arrhythmia using Shensong Yangxin Capsules won the Second-class Prize of the National Science and Technology Progress Award in 2009.


Arrhythmia severely affects the health and the lives of our human beings. There are more than 500,000 cases of sudden deaths in China every year. There have not been any new western drug products for this disease during the recent 20 years. The existing western drug products for arrhythmia are with severe side effects and they even will increase the mortality in some cases. The clinical evidence based medicine studies show that Shensong Yangxin Capsules has excellent therapeutic effects on premature beats and paroxysmal atrial fibrillation and can improve the slow rhythm of the heart. No adverse reactions of the heart are observed. Such clinical symptoms as palpitation, short of breath and insomnia can be significantly alleviated. It has won the praises from the doctors and the patients. It has become the leading brand in the treatment of arrhythmia in China.

  • The evidence based medicine studies have proved that it is a kind of safe product for the effective treatment of premature beats, paroxysmal atrial fibrillation and bradycardiac arrhythmia.
  • It is a kind of product for the treatment of arrhythmia with the integrated adjustment actions of multiple ion channels and non-ion channels.
  • It is a kind of patent TCM drug product for the treatment of arrhythmia that has won a Second-class Prize of the National Science and Technology Progress Award.
  • Listed in the List of National Essential Drugs
  • A Class A Product in the National Health Insurance Program
  • A High-tech Product of the Ministry of Science and Technology
  • A National Level Key New Product
  • Listed in the List of Community Health Products of the Ministry of Health
  • A Key National Project for Key Drug Innovation of the "Eleventh Five-Year Plan"
  • A Key National Project for Key Drug Innovation of the "Twelfth Five-Year Plan"
  • A Key Achievement Transformation Project of the National Ministry of Industry and Information
Guideline/Standard Therapy/Clinical Route
Guideline on Reasonable Medication for Arrhythmia (Second Edition)
Textbooks
  • Integrated Chinese and Western Internal Medicine (Edition III, New Century)
  • Internal Medicine (Edition IX)
Expert Consensus Documents
  • Atrial Fibrillation, Present Understanding and Treatment Recommendations (2018)
  • Chinese Expert Consensus Document on Ventricular Arrhythmia (2016)
  • Expert Consensus Document on Diagnosis and Treatment of Acute Myocardium Infarction through Integrated Chinese and Western Medicine
Study Organizations: 32 Tier Three Class A Hospitals Led by Fuwai Hospital of Chinese Academy of Medical Sciences, Beijing Chaoyang Hospital and No. 1 Affiliated Hospital of Nanjing Medical University

Fast Actions In 859 cases of ventricular premature beat: the overall effective rate of Shensong Yangxin is 65.8%, which is better than that of Mexiletine (50.7%), and in 349 cases of paroxysmal atrial fibrillation the effective rate of Shensong Yangxin is equivalent to that of Propafenone, 62.3% vs 58.6%, but the improvements in the symptoms are better than those of Propafenone.
Levelling
Bradycardiac In 268 cases of chronic bradycardiac arrhythmia, the overall effective rate of Shensong Yangxin is 63.5% and the average ventricular rate improvement is 7.09/minute. The lower the ventricular rate, the more significant the improvement will be.

If a patient suffers from both sinus bradycardia and ventricular premature beat, it would be in a kind of dilemma for the treatment with western drug products. The treatment of ventricular premature beat will worsen sinus bradycardia. The results of a Random, Double Blind, Placebo Control and Multi-center Study on Treatment of Sinus Bradycardia Accompanied with Premature Beat by Shensong Yangxin Capsules were issued on the 15th International Arrhythmia Conference held in Beijing National Convention Center on September 17th, 2015. This evidence based medicine study was held with Academician Zhang Boli, Academician Gao Runlin, Professor Huang Congxin and Professor Zhang Shu as the consultants. It was led by Professor Cao Kejiang of the No. 1 Affiliated Hospital of Nanjing Medical University and participated by 44 Tier Three Class A hospitals in 19 provinces, direct-controlled municipalities or autonomous regions all around the country. It lasted for three years and has been registered at ClinicalTrials.gov in the US. The results show that the reduction in the premature beats is 1,827 beats/24 hours in the treatment group using Shensong Yangxin Capsules, which is better than the 638 beats/24 hours in the control group, the premature beat reduction rate in the treatment group is 71.01%, which is better than the 28.15% in the control group, the improvement in the heart rate is 6.25 beats/minute in the treatment group, which is better than the 2.56 beats/minute in the control group, and the heart rate improvement rate is 11.38% in the treatment group, which is better than the 4.64% in the control group. This proves that this product can improve the sinus bradycardia while safely and effectively improve the ventricular premature beat. It is very suitable to be used for patients suffering from sinus bradycardia accompanied by ventricular premature beat and filled a gap in the therapeutic drug products for the treatment of sinus bradycardia accompanied by premature beat.

A multi-center, random, double blind and placebo control clinical trial has been performed on the outcomes of the treatment of patients suffering from atrial fibrillation after radiofrequency ablation of by Shensong Yangxin Capsules.

This study was led by Professor Huang He of the People's Hospital of Wuhan University.

The clinical study showed that Shensong Yangxin Capsules is safe and effective in the treatment of heart failure accompanied by ventricular premature beat.

The study results show that the reduction of the ventricular premature beat rate is significantly improved as shown by the 24-hour dynamic electrocardiogram, the heart functions are improved, the left ventricular ejection fraction is improved, and the safety is satisfactory in the treatment group. The difference from that of the control group is significant. A multi-center, random, double blind and placebo control clinical trial is to be performed in more than 30 Tier Three Class A hospitals all around the country and 400 subjects are expected to be enrolled. The international standards are followed for the study. The recurrence rate of atrial fibrillation 1 year after ablation is used as the major end point. The outcomes of the 1-year continuous medication after radiofrequency ablation for the patient with atrial fibrillation will be monitored and the relevant hospitalization rate and cardiovascular events will also be monitored to evaluate the impacts of Shensong Yangxin Capsules on the outcomes of the patients suffering from atrial fibrillation after radiofrequency ablation in a more thorough and systematic way.

   Read this leaflet carefully, and take this medicine under the doctor or  pharmacists’ direction

  [Drug Name]

  Generic name : Shensong Yangxin Capsules

  Chinese Pinyin: Shensong Yangxin Jiaonang

  [Ingredients] Ginseng, Dwarf Lilyturf Turber, Asiatic Cornelian Cherry  Fruit, Danshen Root, Spine Date Seed (Stir-baked), Chinese Taxillus Herb, Red  Peony Root, Ground beetle, Nardostachys Root, Golden Thread, Southern  Magnoliavine Fruit, Fossilizid

  [Description] Capsules containing yellowish-brown to brown granules and  powder; taste, bitter.

  [Functions and Indications] Replenish qi and tonify yin, activate blood and  free the collateral vessels, nourish the heart to tranquilize. Indicated for  ventricular premature beat (VPB) belonging to meridian obstruction syndrome with  deficiency of both qi and yin, with the symptoms of palpitation, shortness of  breath and hypodynamia, aggravated after moving, oppressed feelings in the   precordial region, insomnia and dream disturbed sleep, night sweating, fatigue  and lassitude.

  [Strength] 0.4g/capsule

  [Administration and Dosage] For oral administration, 2-4 capsules once, 3  times daily.

  [Adverse Reactions] Gastrectasia may emerge in individual patient.

  [Contraindications] Unclear.

  [Precautions] This drug should combine with other medicine to the treatment  of the primary disease which caused arrhythmia. Please protect from moisture  after opening the moisture proof bag.

  [Pharmacology and Toxicology] Preclinical & pharmacological tests  showed that: This product can reduce the incidence of arrhythmia caused by CaCl2  in mice; shorten the duration of arrhythmia induced by aconitine in rats;  increase the application amount of Ouabain, when making the model of the  ventricular premature beat (VPB), ventricular tachycardia (VT) and ventricular  fibrillation (VF) in guinea pigs. For rat myocardial ischemia-reperfusion injury   model, it can reduce the severity of arrhythmia, decrease the serum levels of  CK, LDH and MDA, increase the serum SOD and myocardial Na+, K+-ATP activity. It  can also reduce the blood pressure, coronary artery resistance and myocardial  oxygen consumption of anesthetized dogs. It can also shorten the length and  reduce the weight of thrombosis of rats in vitro. [Storage] Preserve in tightly  closed containers.

  [Package] Aluminum-plastic package, 12 capsules/blister, 2 blister/box.

  [Shelf-life] 24 months

  [Executive Standard] Chinese Pharmacopoeia 2010, the 2nd supplemental  volume.

  [Approval No.] GYZZ Z20103032

  [Manufacturer]

  Company name: Beijing Yiling Pharmaceutical Co., Ltd.

  Manufacture address: No. 17 Tianfu street, Bio-medical base, Zhongguancun  science & technology zone, Daxing district, Beijing, China.

  Postcode: 102600

  Tel: 800 8038581 +86 10 59705130 400 8165108 400 8165109

  Fax: + 86 10 59705129

  Registration address: No. 19 Tianhe west road, Bio-medical base, Daxing  district, Beijing, China.

  Website: http://www.yiling.cn

  Beijing Yiling Pharmaceutical Co., Ltd.